Loading
A phase 2/3 trial testing BNT113 in head and neck squamous cell carcinoma, active and no longer recruiting.
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 is a phase 2/3 interventional study registered as NCT04534205, led by BioNTech SE, and active but no longer recruiting on the registry. Official title: An Open-label Phase II/III Randomised Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1. Planned enrolment is 358 participants (actual). The study started in 2021-01-07 and primary completion is expected in 2028-08. No results have been posted on ClinicalTrials.gov.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares HPV-positive oropharyngeal cancer, Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.